{
    "clinical_study": {
        "@rank": "110801", 
        "arm_group": [
            {
                "arm_group_label": "Mycophenolate mofetil + Belimumab", 
                "arm_group_type": "Experimental", 
                "description": "All patients who enroll in this trial will FIRST receive mycophenolate mofetil (MMF, Cellcept), which is a drug commonly given to patients with scleroderma in clinical practice. This drug will be given at no cost to the patient. After the patient has been titrated to 2 grams of MMF per day, the patient will receive EITHER a 10 mg/kg belimumab (Benlysta) intravenous infusion OR a placebo (saline) infusion. This medication and infusion will of course be covered by the study."
            }, 
            {
                "arm_group_label": "Mycophenolate Mofetil + Saline (placebo)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "In order to observe the difference between belimumab/MMF compared to MMF alone, half of the patients will receive a normal saline infusion that appears identical to the belimumab infusion."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a 48 week, phase IIa, single center, randomized, double-blind, placebo-controlled,\n      proof-of-concept pilot study. All participants will first be treated with mycophenolate\n      mofetil (MMF, Cellcept) and titrated up to a dose of 2 grams/day. Following this period,\n      half will be given either a belimumab (Benlysta\u00ae) or placebo intravenous infusion to treat\n      early diffuse cutaneous systemic sclerosis. Belimumab/MMF is expected to improve disease\n      activity measured by an improvement in skin thickening and stability of pulmonary function\n      test measurements when compared to patients treated with placebo/MMF."
        }, 
        "brief_title": "Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Systemic Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Scleroderma, Systemic", 
                "Scleroderma, Diffuse", 
                "Sclerosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The specific objectives of this study are to:\n\n        1. Determine whether belimumab used in combination with MMF is safe and tolerable in the\n           treatment of patients with early diffuse cutaneous systemic sclerosis (Disease duration\n           < 3 years).\n\n        2. Determine whether belimumab used in combination with MMF is more effective in the\n           treatment of diffuse cutaneous systemic sclerosis than MMF alone, as measured by change\n           in modified Rodnan Skin Score (mRSS), forced vital capacity (FVC), hemoglobin corrected\n           diffusion capacity (DLCO), Medsger Severity Scale (MSS), and by other physician and\n           patient derived outcome measures.\n\n        3. Determine the biological activity of Belimumab/MMF as assessed by effect on histology\n           of skin, change in B-Cell profiles, effect on BLyS levels, and effect on serological\n           and cutaneous biomarkers of disease activity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age greater than or equal to eighteen years.\n\n          2. Clinical diagnosis of diffuse systemic sclerosis by ACR criteria, with a  stable\n             modified Rodnan skin score in the one month preceding introduction of belimumab\n             therapy.\n\n          3. Disease duration of less than or equal to 3 years as defined by the date of onset of\n             the first non-Raynaud's symptom.\n\n        Exclusion Criteria:\n\n          1. Inability to render informed consent in accordance with institutional guidelines.\n\n          2. Disease duration of greater than 3 years.\n\n          3. Patients with mixed connective tissue disease or \"overlap\" (i.e. those who satisfy\n             more than one set of ACR criteria for a rheumatic disease.)\n\n          4. Limited scleroderma.\n\n          5. Systemic sclerosis-like illness associated with environmental or ingested agents such\n             as toxic rapeseed oil, vinyl chloride, or bleomycin.\n\n          6. Ongoing treatment with immunosuppressive therapies including cyclophosphamide,\n             azathioprine, methotrexate, or cyclosporine, or use of those medications within 1\n             month of trial entry.\n\n          7. The use of other anti-fibrotic agents including colchicine, D-penicillamine,\n             minocycline, tyrosine kinase inhibitors (nilotinib, imatinib, dasatinib), or Type 1\n             oral Collagen in the month prior to enrollment.\n\n          8. Use in the prior month of corticosteroids at doses exceeding the equivalent of\n             prednisone 10 mg daily. Use of corticosteroid at < 10 mg of prednisone can continue\n             during the course of the study.\n\n          9. Treatment with MMF at a dose of \u2265 2 grams daily for > 3 months.\n\n         10. Concurrent serious medical condition which in the opinion of the investigator makes\n             the patient inappropriate for this study such as uncontrollable CHF, arrhythmia,\n             severe pulmonary or systemic hypertension, severe GI involvement, hepatic impairment,\n             serum creatinine of greater than 2.0, active infection, severe diabetes, unstable\n             atherosclerotic cardiovascular disease, malignancy, HIV, or severe peripheral\n             vascular disease.\n\n         11. A positive pregnancy test at entry into this study.\n\n         12. Men and women with reproductive potential will be required to use effective means of\n             contraception through the course of the study, such as a tubal ligation or\n             hysterectomy, condom or diaphragm used with a spermicide,or an intrauterine device\n             (IUD). Approved hormonal contraceptives (such as birth control pills, patches,\n             implants or injections) may interact with and reduce the effectiveness of MMF and\n             thus, are not acceptable. Contraceptive measures such as Plan B (TM), sold for\n             emergency use after unprotected sex, are not acceptable methods for routine use.\n\n         13. Breastfeeding. Breastfeeding is contraindicated with the use of MMF.\n\n         14. Participation in another clinical research study involving the evaluation of another\n             investigational drug within ninety days of entry into this study.\n\n         15. The presence of severe lung disease as defined by a diffusion capacity of less than\n             30% of predicted or requiring supplemental oxygen.\n\n         16. History of HIV infection\n\n         17. Known active bacterial, viral, fungal, mycobacterial, or other infection r any major\n             episode of infection requiring hospitalization or treatment with IV antibiotics\n             within 4 weeks of screening, or oral antibiotics within 2 weeks prior to screening\n\n         18. Any other disease, metabolic dysfunction, physical examination finding, or clinical\n             laboratory finding giving reasonable suspicion of a disease or condition that\n             contraindicates the use of an investigational drug or that may affect the\n             interpretation of the results or render the patient at high risk from treatment\n             complications\n\n         19. Prior use of Belimumab, Rituximab, or other B-Cell depleting therapies ever\n\n         20. The use of other biologics including TNF inhibitors, abatacept, or tocilizumab within\n             1 month of enrollment [this is a safety issue]\n\n         21. Patients with a history of severe depression, psychosis, or suicidal ideation will be\n             excluded."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01670565", 
            "org_study_id": "12006"
        }, 
        "intervention": {
            "arm_group_label": "Mycophenolate mofetil + Belimumab", 
            "description": "Belimumab (Benlysta\u00ae) decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. Prior research provides a robust rationale for the investigation of belimumab in combination with MMF (Cellcept \u00ae) for the treatment of early diffuse cutaneous systemic sclerosis.", 
            "intervention_name": "Belimumab", 
            "intervention_type": "Drug", 
            "other_name": "Benlysta"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Mycophenolate mofetil", 
                "Mycophenolic Acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diffuse cutaneous systemic sclerosis", 
            "Early Diffuse cutaneous systemic sclerosis"
        ], 
        "lastchanged_date": "January 15, 2014", 
        "link": {
            "description": "Scleroderma, Vasculitis, & Myositis Center Website", 
            "url": "http://www.hss.edu/scleroderma-vasculitis-center.asp"
        }, 
        "location": {
            "contact": {
                "email": "lernerd@hss.edu", 
                "last_name": "Daniele Lerner, BA", 
                "phone": "646-714-6302"
            }, 
            "contact_backup": {
                "email": "paddun@hss.edu", 
                "last_name": "Nina Paddu, BA", 
                "phone": "212-774-7194"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Hospital for Special Surgery"
            }, 
            "investigator": [
                {
                    "last_name": "Robert Spiera, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jessica Gordon, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis: A Phase 2a, Single-centered, Randomized, Placebo-controlled, Double-blind, Proof-of-concept Pilot Study.", 
        "overall_contact": {
            "email": "spierar@hss.edu", 
            "last_name": "Robert Spiera, MD", 
            "phone": "2127742048"
        }, 
        "overall_official": {
            "affiliation": "Hospital for Special Surgery, New York", 
            "last_name": "Robert Spiera, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The efficacy of the drug will be measured as the change in the Modified Rodnan Skin Score (MRSS) at 48 weeks. MRSS is a measurement of the degree of skin disease in systemic sclerosis where 17 areas of skin are rated by the examiner.", 
                "measure": "Change in Modified Rodnan Skin Score", 
                "safety_issue": "No", 
                "time_frame": "At 48 weeks"
            }, 
            {
                "description": "The safety and tolerability of belimumab in patients with systemic sclerosis will be as assessed by comparing the rates of adverse and serious adverse events between treatment and placebo groups.", 
                "measure": "Number of Participants with Adverse and Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "At 52 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01670565"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital for Special Surgery, New York", 
            "investigator_full_name": "Robert Spiera, MD", 
            "investigator_title": "Director of Scleroderma, Vasculitis and Myositis Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "This endpoint would measure the change in forced vital capacity and diffusion capacity of the pulmonary function test (the breathing test)", 
                "measure": "Change in Pulmonary Function Test Measures", 
                "safety_issue": "No", 
                "time_frame": "At 24 and 48 weeks"
            }, 
            {
                "description": "This Medsger Severity Scale(MSS)is an objective method of assessing disease severity in patients with systemic sclerosis.", 
                "measure": "Change in the Medsger Severity Scale", 
                "safety_issue": "No", 
                "time_frame": "At 24 and 48 weeks"
            }, 
            {
                "description": "The Scleroderma Health Assessment Questionnaire (SHAQ) is a patient survey which indexes the participants degree of disability. The Short Form-36 is a questionnaire that addresses the patient's health-related quality of life. The Raynaud's Condition Score is a measure of the degree to which the patient's Raynaud's affects his or her daily functioning.", 
                "measure": "Change in the Scleroderma Health Assessment Questionnaire, Short Form-36, and Raynaud's Condition Score", 
                "safety_issue": "No", 
                "time_frame": "At each visit"
            }
        ], 
        "source": "Hospital for Special Surgery, New York", 
        "sponsors": {
            "collaborator": {
                "agency": "Human Genome Sciences Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Hospital for Special Surgery, New York", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}